ArticleAntibiotics (Basel, Switzerland)2018
Fighting Fire with Fire: Phage Potential for the Treatment of
Article in Antibiotics (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Type VI secretion system degeneration accelerates intestinal epithelial cell death in Escherichia coli O157:H7.PLoS pathogens · 2026Article
- Limitations and safety aspects related to the use of bacteriophages in food production.FEMS microbiology reviews · 2026Article
- Article
- Article
- Isolation, characterization, and receptor-binding protein specificity of phages PAS7, PAS59 and PAS61 infecting Shiga toxin-producing Escherichia coli O103 and O146.Scientific reports · 2024Article
- Selective bacteriophages reduce the emergence of resistant bacteria in bacteriophage-antibiotic combination therapy.Microbiology spectrum · 2024Article
- An in vitro fermentation model to study the impact of bacteriophages targeting Shiga toxin-encoding Escherichia coli on the colonic microbiota.NPJ biofilms and microbiomes · 2022Article
- Synergistic Effects of Bacteriophage vB_Eco4-M7 and Selected Antibiotics on the Biofilm Formed by Shiga Toxin-ProducingAntibiotics (Basel, Switzerland) · 2022Article
- ABToxins · 2022Review
- The interactions of bacteriophage Ace and Shiga toxin-producing Escherichia coli during biocontrol.FEMS microbiology ecology · 2021Article
- Revisiting the rules of life for viruses of microorganisms.Nature reviews. Microbiology · 2021Review
- Anti-biofilm and Antibacterial Activity ofIndian journal of microbiology · 2019Article
- Complete Genome Sequences of Escherichia coli Phages vB_EcoM-EP75 and vB_EcoP-EP335.Microbiology resource announcements · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
Hemolytic⁻uremic syndrome is a life-threating disease most often associated with Shiga toxin-producing microorganisms like
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.